4.7 Review

miRNA-Directed Regulation of the Main Signaling Pathways in Thyroid Cancer

Journal

FRONTIERS IN ENDOCRINOLOGY
Volume 10, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2019.00430

Keywords

miRNAs; MAPK; P13K; TGF beta; thyroid; cancer

Funding

  1. MINECO/FEDER, UE [SAF2016-75531-R]
  2. Asociacion Espanola Contra el Cancer (AECC) [GCB141423113]
  3. CIBERONC from the Instituto de Salud Carlos III (ISCIII)
  4. Tironet2 (Comunidad de Madrid) [B2017/BMD-3724]
  5. FPU fellowship from Spanish Ministry of Education

Ask authors/readers for more resources

In the last two decades, great strides have been made in the study of microRNAs in development and in diseases such as cancer, as reflected in the exponential increase in the number of reviews on this topic including those on undifferentiated and well-differentiated thyroid cancer Nevertheless, few reviews have focused on understanding the functional significance of the most up- or down-regulated miRNAs in thyroid cancer for the main signaling pathways hyperactivated in this tumor type. The aim of this review is to discuss the major miRNAs targeting proteins of the MAPK, PI3K, and TGF beta pathways, to define their mechanisms of action through the 3'UTR regions of their target genes, and to describe how they affect thyroid tumorigenesis through their actions on cell proliferation, migration, and invasion. Given the importance of miRNAs in cancer as diagnostic, prognostic and therapeutic candidates, a better understanding of this cross-talk might shed new light on the biomedical treatment of thyroid cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN

Julia Ramirez-Moya, Leon Wert-Lamas, Pilar Santisteban

ONCOGENE (2018)

Article Multidisciplinary Sciences

mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis

Junho Choe, Shuibin Lin, Wencai Zhang, Qi Liu, Longfei Wang, Julia Ramirez-Moya, Peng Du, Wantae Kim, Shaojun Tang, Piotr Sliz, Pilar Santisteban, Rani E. George, William G. Richards, Kwok-Kin Wong, Nicolas Locker, Frank J. Slack, Richard I. Gregory

NATURE (2018)

Article Biochemistry & Molecular Biology

Impaired microRNA processing by DICER1 downregulation endows thyroid cancer with increased aggressiveness

Julia Ramirez-Moya, Leon Wert-Lamas, Garcilaso Riesco-Eizaguirre, Pilar Santisteban

ONCOGENE (2019)

Article Multidisciplinary Sciences

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Julia Ramirez-Moya, Leon Wert-Lamas, Adrian Acuna-Ruiz, Miguel A. Zabellos, Pilar Santisteban

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2019)

Article Biochemistry & Molecular Biology

ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity

Julia Ramirez-Moya, Allison R. Baker, Frank J. Slack, Pilar Santisteban

ONCOGENE (2020)

Article Endocrinology & Metabolism

A Positive Feedback Loop Between DICER1 and Differentiation Transcription Factors Is Important for Thyroid Tumorigenesis

Julia Ramirez-Moya, Pilar Santisteban

Summary: The study revealed a molecular link between DICER1 and thyroid cell differentiation pathways, showing that DICER1 forms a positive feedback loop with differentiation transcription factors NKX2.1, PAX8, and CREB. This interaction affects thyroid cancer progression and treatment, providing insights into the downregulation of DICER1 in thyroid cancer.

THYROID (2021)

Article Biochemistry & Molecular Biology

An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks

Julia Ramirez-Moya, Christos Miliotis, Allison R. Baker, Richard Gregory, Frank J. Slack, Pilar Santisteban

Summary: ADAR1 deregulation leads to increased A-to-I editing in thyroid tumors, with CDK13 being identified as an oncogene that is significantly over-edited in tumor samples. This editing event promotes cancer cell hallmarks and increases the nucleolar abundance of the protein, potentially explaining the global splicing changes induced by ADAR1 deregulation.

MOLECULAR CANCER (2021)

Article Endocrinology & Metabolism

Circulating MicroRNA Profiles as Potential Biomarkers for Differentiated Thyroid Cancer Recurrence

Jelena Jankovic Miljus, Maria Augusta Guillen-Sacoto, Jennifer Makiadi-Alvarado, Leon Wert-Lamas, Julia Ramirez-Moya, Mercedes Robledo, Pilar Santisteban, Garcilaso Riesco-Eizaguirre

Summary: This study identified two putative novel miRNAs that rise with rhTSH stimulation in the serums of patients with recurrent/persistent thyroid cancer. However, known miRNAs were not found to be circulating markers for thyroid cancer recurrence.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Oncology

Transcriptome Profiling of ADAR1 Targets in Triple-Negative Breast Cancer Cells Reveals Mechanisms for Regulating Growth and Invasion

Allison R. Baker, Christos Miliotis, Julia Ramirez-Moya, Talia Marc, Ioannis S. Vlachos, Pilar Santisteban, Frank J. Slack

Summary: ADAR1 plays a critical role in triple-negative breast cancer, and its loss leads to reduced cell growth, invasion, and mammosphere formation. ADAR1 regulates both coding and noncoding targets by altering gene expression level, A-to-I editing, and splicing. The study also reveals that several tumor suppressor miRNAs are upregulated upon ADAR1 loss, suppressing cell-cycle progression and invasion.

MOLECULAR CANCER RESEARCH (2022)

Article Multidisciplinary Sciences

Identification of an interactome network between lncRNAs and miRNAs in thyroid cancer reveals SPTY2D1-AS1 as a new tumor suppressor

Julia Ramirez-Moya, Leon Wert-Lamas, Adrian Acuna-Ruiz, Alice Fletcher, Carlos Wert-Carvajal, Christopher J. McCabe, Pilar Santisteban, Garcilaso Riesco-Eizaguirre

Summary: Thyroid cancer is a rapidly increasing malignancy, and long non-coding RNAs (lncRNAs) play important roles in its progression. SPTY2D1-AS1, a downregulated lncRNA, has been identified as a tumor suppressor in thyroid cancer and a potential therapeutic target.

SCIENTIFIC REPORTS (2022)

No Data Available